The body is dense and mostly high-signal (exact thresholds like 'PRR >= 2.0, N >= 3, lower CI > 1.0', tool names, scoring component weights) without explaining concepts Claude already knows, but it is long and defers key tables and formulae to external files, so it could be tightened.

It names specific tools and exact signal criteria, which is actionable for tool selection, but all executable Python code and the actual 0-100 scoring rubric are deferred to PHASE_DETAILS.md — providing some concrete guidance but missing key executable details.

The ten-phase pipeline is clearly sequenced with an ASCII flow diagram and an edge-cases section, but this batch analysis lacks explicit inter-phase validation checkpoints (e.g. verify N>=3 before proceeding), which the rubric says should cap workflow clarity at 2 for batch operations.

The body explicitly defers the signal-classification table, scoring rubric, code examples, and report template to PHASE_DETAILS.md, REPORT_TEMPLATE.md, TOOL_REFERENCE.md, and QUICK_START.md, but none of these referenced files actually exist in the bundle, so the promised one-level-deep detail is unreachable.

Lists multiple concrete actions ('Detect and analyze adverse drug event signals', 'Generates quantitative safety signal scores (0-100) with evidence grading') with named data sources (FAERS, drug labels) and statistics (PRR, ROR, IC), matching the anchor for listing multiple specific concrete actions.

Explicitly answers both what (detect/quantify/grade safety signals) and when via an explicit 'Use for ...' clause listing concrete scenarios, matching the anchor for clearly answering both with explicit triggers.

Covers natural terms users would say — 'post-market surveillance', 'pharmacovigilance', 'drug safety assessment', 'regulatory submissions', 'adverse drug event signals' — giving good coverage rather than technical jargon.

Occupies a clear niche — FAERS disproportionality analysis plus a quantitative Safety Signal Score — that is unlikely to trigger the wrong skill; the body even differentiates it from a sibling pharmacovigilance skill.